Literature DB >> 8004383

Pharmacokinetics, plasma protein binding and urinary excretion of N omega-nitro-L-arginine in rats.

M A Tabrizi-Fard1, H L Fung.   

Abstract

The in vivo disposition of N omega-nitro-L-arginine (L-NOARG) has been examined in rats. Plasma concentrations of L-NOARG following an intravenous dose of 10 mg kg-1 were determined by high-performance liquid chromatography. Plasma L-NOARG concentrations declined biexponentially, with average half-lives of 11 min and 20 h. L-NOARG clearance did not appear to exhibit concentration-dependency below a plasma concentration of 4.56 x 10(-4) M (100 mg l-1). Ultrafiltration studies revealed insignificant binding of L-NOARG to rat plasma proteins. Urinary excretion of unchanged L-NOARG was minimal. These pharmacokinetic information may be useful in the design of in vivo experiments involving L-NOARG, as well as in the interpretation of the pharmacodynamics of this important nitric oxide synthase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004383      PMCID: PMC1909953          DOI: 10.1111/j.1476-5381.1994.tb14747.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

Review 1.  Overproduction of nitric oxide in cytokine-mediated and septic shock.

Authors:  R G Kilbourn; O W Griffith
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

2.  l-NG-nitro-arginine methyl ester in the anesthetized rabbit: venous vasomotion and plasma levels.

Authors:  S Schwarzacher; G Raberger
Journal:  J Vasc Res       Date:  1992 May-Jun       Impact factor: 1.934

Review 3.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

4.  Phasic and 24-h blood pressure control by endothelium-derived relaxing factor in conscious dogs.

Authors:  P B Persson; J E Baumann; H Ehmke; B Nafz; U Wittmann; H R Kirchheim
Journal:  Am J Physiol       Date:  1992-05

5.  NG-nitro-L-arginine pharmacokinetics in rats after a single intravascular and oral dose: an appearance of secondary concentration time peaks.

Authors:  V K Piotrovskij; Z Kállay; K Krejcy; J Horecký; T Trnovec; G Raberger
Journal:  Drug Metab Dispos       Date:  1993 Sep-Oct       Impact factor: 3.922

6.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

7.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

Authors:  Y A Kolesnikov; C G Pick; G Ciszewska; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

  8 in total
  5 in total

1.  Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus.

Authors:  M A Bush; G M Pollack
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon.

Authors:  S Cellek; J Rodrigo; E Lobos; P Fernández; J Serrano; S Moncada
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis.

Authors:  M A Tabrizi-Fard; H L Fung
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

4.  Induction of diaphragmatic nitric oxide synthase after endotoxin administration in rats: role on diaphragmatic contractile dysfunction.

Authors:  J Boczkowski; S Lanone; D Ungureanu-Longrois; G Danialou; T Fournier; M Aubier
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

5.  Zerumbone Alleviates Neuropathic Pain through the Involvement of l-Arginine-Nitric Oxide-cGMP-K⁺ ATP Channel Pathways in Chronic Constriction Injury in Mice Model.

Authors:  Nurul Atiqah Zulazmi; Banulata Gopalsamy; Jasmine Chia Siew Min; Ahmad Akira Omar Farouk; Mohd Roslan Sulaiman; B Hemabarathy Bharatham; Enoch Kumar Perimal
Journal:  Molecules       Date:  2017-03-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.